Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
The impact of the SARS-CoV-2 pandemic on children remains unclear. Better understanding of the burden of COVID-19 among children and their risk of reinfection is crucial, as they will be among the last groups vaccinated. To characterize the burden of COVID-19 and assess how risk of symptomatic reinfection may vary by age among children. In this prospective, community-based pediatric cohort study conducted from March 1, 2020, to October 15, 2021, 1964 nonimmunocompromised children aged 0 to 14 years were enrolled by random selection from the Nicaraguan Pediatric Influenza Cohort, a community-based cohort in District 2 of Managua, Nicaragua. Additional newborn infants aged 4 weeks or younger were randomly selected and enrolled monthly via home visits. Prior COVID-19 infection as confirmed by positive anti-SARS-CoV-2 antibodies (receptor binding domain and spike protein) or real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 infection at least 60 days before current COVID-19 infection. Symptomatic COVID-19 cases confirmed by real-time RT-PCR and hospitalization within 28 days of symptom onset of a confirmed COVID-19 case. This cohort study assessed 1964 children (mean [SD] age, 6.9 [4.4] years; 985 [50.2%] male). Of 1824 children who were tested, 908 (49.8%; 95% CI, 47.5%-52.1%) were seropositive during the study. There were also 207 PCR-confirmed COVID-19 cases, 12 (5.8%) of which were severe enough to require hospitalization. Incidence of COVID-19 was highest among children younger than 2 years (16.1 cases per 100 person-years; 95% CI, 12.5-20.5 cases per 100 person-years), which was approximately 3 times the incidence rate in any other child age group assessed. In addition, 41 symptomatic SARS-CoV-2 episodes (19.8%; 95% CI, 14.4%-25.2%) were reinfections. In this prospective, community-based pediatric cohort study, rates of symptomatic and severe COVID-19 were highest among the youngest participants, with rates stabilizing at approximately 5 years of age. In addition, symptomatic reinfections represented a large proportion of symptomatic COVID-19 cases.
Identifiants
pubmed: 35759261
pii: 2793625
doi: 10.1001/jamanetworkopen.2022.18794
pmc: PMC9237791
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2218794Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Références
Epidemiol Infect. 2021 Oct 20;149:e247
pubmed: 35172912
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Pediatr Pulmonol. 2021 Aug;56(8):2495-2502
pubmed: 34102037
Pediatr Infect Dis J. 2021 Jan;40(1):e7-e11
pubmed: 33093428
Sci Rep. 2021 May 13;11(1):10231
pubmed: 33986390
Am J Epidemiol. 1990 Feb;131(2):373-5
pubmed: 2296988
BMC Infect Dis. 2015 Nov 09;15:504
pubmed: 26553094
Swiss Med Wkly. 2021 Sep 17;151:w30058
pubmed: 34546012
Influenza Other Respir Viruses. 2022 Jan;16(1):34-47
pubmed: 34796674
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
Clin Infect Dis. 2022 Aug 24;75(1):e257-e266
pubmed: 34411230
J Athl Train. 2021 Jun 1;56(6):542-547
pubmed: 34375980
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Arch Dis Child. 2021 Jul;106(7):680-686
pubmed: 33172887
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Aging Male. 2020 Dec;23(5):1416-1424
pubmed: 32508193
JAMA Pediatr. 2021 Feb 1;175(2):176-184
pubmed: 33226415
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Int J Pediatr. 2020 Nov 18;2020:9680905
pubmed: 33299428
Ital J Pediatr. 2021 Aug 26;47(1):177
pubmed: 34446085
BMC Pediatr. 2021 Mar 25;21(1):144
pubmed: 33765980
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
JAMA Netw Open. 2021 Sep 1;4(9):e2124343
pubmed: 34491353
Int J Pediatr. 2021 Oct 06;2021:2185161
pubmed: 34659422
Science. 2021 Feb 12;371(6530):741-745
pubmed: 33436525
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339